Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

12.26USD
2:08pm EST
Change (% chg)

$0.33 (+2.77%)
Prev Close
$11.93
Open
$12.00
Day's High
$12.50
Day's Low
$11.94
Volume
47,066
Avg. Vol
96,083
52-wk High
$27.08
52-wk Low
$9.40

Select another date:

Thu, Nov 3 2016

BRIEF-Esperion Therapeutics reports qtrly loss per share $0.77

* Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

BRIEF-BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics

* BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Esperion Therapeutics reports Q2 net loss of $14 mln

* Estimates current cash resources are sufficient to fund operations into 2019

BRIEF-Esperion Therapeutics provides regulatory update for Bempedoic Acid

* Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016

Select another date: